Semra Fırat, Şükran Erten, Serdar Can Güven, Sezen Tutar, Yüksel Maraş, Salim Neşelioğlu, Selçuk Akan, Ahmet Kor, Berkan Armağan, Kevser Orhan, İsmail Doğan, Orhan Küçükşahin, Özcan Erel
{"title":"生物治疗对轴向脊柱关节炎患者体内硫醇/二硫化物参数的影响","authors":"Semra Fırat, Şükran Erten, Serdar Can Güven, Sezen Tutar, Yüksel Maraş, Salim Neşelioğlu, Selçuk Akan, Ahmet Kor, Berkan Armağan, Kevser Orhan, İsmail Doğan, Orhan Küçükşahin, Özcan Erel","doi":"10.1080/08923973.2025.2469211","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Aim of this study is to compare the thiol/disulfide variables before treatment, at the 3<sup>rd</sup> and 6<sup>th</sup> months of biologic treatment in patients with axSpA.</p><p><strong>Materials & methods: </strong>Consecutive patients with axial spondyloarthritis to whom biologic treatment was initiated in our clinic were enrolled upon consent. Demographics, clinical characteristics, laboratory parameters and treatment agents were collected. Disease activity scores and thiol-disulfide balance parameters were recorded at baseline and 3<sup>rd</sup>, 6<sup>th</sup> months of treatment. Statistical analyses were performed in all patients and in subgroups of ankylosing spondylitis and non-radiographic axial spondyloarthritis patients.</p><p><strong>Results: </strong>In all patients, total thiol levels were significantly increased at 6<sup>th</sup> month in comparison to baseline values (470.5 ± 74.7 vs 491.9 ± 69.6, <i>p</i> = 0.047). Native thiol levels were increased at 6<sup>th</sup> month close to significance (438.9 ± 70.4 vs 458.8 ± 63.7, <i>p</i> = 0.060). Moderately strong negative correlations were observed between native thiol levels and disease activity parameters (BASDAI: <i>p</i> = 0,019; ASDAS-CRP: <i>p</i> = 0,035; ASDAS-ESR: <i>p</i> = 0,030), and between total thiol levels and disease activity parameters (BASDAI: <i>p</i> = 0,031; ASDAS-CRP: <i>p</i> = 0,020; ASDAS-ESR: <i>p</i> = 0,026) at 6<sup>th</sup> month evaluation.</p><p><strong>Discussion & conclusions: </strong>Our results demonstrated oxidative stress reducing effect of biologics in axSpA patients parallel to suppression of disease activity at 6<sup>th</sup> month of the treatment.</p>","PeriodicalId":13420,"journal":{"name":"Immunopharmacology and Immunotoxicology","volume":" ","pages":"228-233"},"PeriodicalIF":2.9000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of biological treatment on the thiol/disulfide parameters in patients with axial spondyloarthritis.\",\"authors\":\"Semra Fırat, Şükran Erten, Serdar Can Güven, Sezen Tutar, Yüksel Maraş, Salim Neşelioğlu, Selçuk Akan, Ahmet Kor, Berkan Armağan, Kevser Orhan, İsmail Doğan, Orhan Küçükşahin, Özcan Erel\",\"doi\":\"10.1080/08923973.2025.2469211\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Aim of this study is to compare the thiol/disulfide variables before treatment, at the 3<sup>rd</sup> and 6<sup>th</sup> months of biologic treatment in patients with axSpA.</p><p><strong>Materials & methods: </strong>Consecutive patients with axial spondyloarthritis to whom biologic treatment was initiated in our clinic were enrolled upon consent. Demographics, clinical characteristics, laboratory parameters and treatment agents were collected. Disease activity scores and thiol-disulfide balance parameters were recorded at baseline and 3<sup>rd</sup>, 6<sup>th</sup> months of treatment. Statistical analyses were performed in all patients and in subgroups of ankylosing spondylitis and non-radiographic axial spondyloarthritis patients.</p><p><strong>Results: </strong>In all patients, total thiol levels were significantly increased at 6<sup>th</sup> month in comparison to baseline values (470.5 ± 74.7 vs 491.9 ± 69.6, <i>p</i> = 0.047). Native thiol levels were increased at 6<sup>th</sup> month close to significance (438.9 ± 70.4 vs 458.8 ± 63.7, <i>p</i> = 0.060). Moderately strong negative correlations were observed between native thiol levels and disease activity parameters (BASDAI: <i>p</i> = 0,019; ASDAS-CRP: <i>p</i> = 0,035; ASDAS-ESR: <i>p</i> = 0,030), and between total thiol levels and disease activity parameters (BASDAI: <i>p</i> = 0,031; ASDAS-CRP: <i>p</i> = 0,020; ASDAS-ESR: <i>p</i> = 0,026) at 6<sup>th</sup> month evaluation.</p><p><strong>Discussion & conclusions: </strong>Our results demonstrated oxidative stress reducing effect of biologics in axSpA patients parallel to suppression of disease activity at 6<sup>th</sup> month of the treatment.</p>\",\"PeriodicalId\":13420,\"journal\":{\"name\":\"Immunopharmacology and Immunotoxicology\",\"volume\":\" \",\"pages\":\"228-233\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immunopharmacology and Immunotoxicology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/08923973.2025.2469211\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/21 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunopharmacology and Immunotoxicology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08923973.2025.2469211","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/21 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Effect of biological treatment on the thiol/disulfide parameters in patients with axial spondyloarthritis.
Objective: Aim of this study is to compare the thiol/disulfide variables before treatment, at the 3rd and 6th months of biologic treatment in patients with axSpA.
Materials & methods: Consecutive patients with axial spondyloarthritis to whom biologic treatment was initiated in our clinic were enrolled upon consent. Demographics, clinical characteristics, laboratory parameters and treatment agents were collected. Disease activity scores and thiol-disulfide balance parameters were recorded at baseline and 3rd, 6th months of treatment. Statistical analyses were performed in all patients and in subgroups of ankylosing spondylitis and non-radiographic axial spondyloarthritis patients.
Results: In all patients, total thiol levels were significantly increased at 6th month in comparison to baseline values (470.5 ± 74.7 vs 491.9 ± 69.6, p = 0.047). Native thiol levels were increased at 6th month close to significance (438.9 ± 70.4 vs 458.8 ± 63.7, p = 0.060). Moderately strong negative correlations were observed between native thiol levels and disease activity parameters (BASDAI: p = 0,019; ASDAS-CRP: p = 0,035; ASDAS-ESR: p = 0,030), and between total thiol levels and disease activity parameters (BASDAI: p = 0,031; ASDAS-CRP: p = 0,020; ASDAS-ESR: p = 0,026) at 6th month evaluation.
Discussion & conclusions: Our results demonstrated oxidative stress reducing effect of biologics in axSpA patients parallel to suppression of disease activity at 6th month of the treatment.
期刊介绍:
The journal Immunopharmacology and Immunotoxicology is devoted to pre-clinical and clinical drug discovery and development targeting the immune system. Research related to the immunoregulatory effects of various compounds, including small-molecule drugs and biologics, on immunocompetent cells and immune responses, as well as the immunotoxicity exerted by xenobiotics and drugs. Only research that describe the mechanisms of specific compounds (not extracts) is of interest to the journal.
The journal will prioritise preclinical and clinical studies on immunotherapy of disorders such as chronic inflammation, allergy, autoimmunity, cancer etc. The effects of small-drugs, vaccines and biologics against central immunological targets as well as cell-based therapy, including dendritic cell therapy, T cell adoptive transfer and stem cell therapy, are topics of particular interest. Publications pointing towards potential new drug targets within the immune system or novel technology for immunopharmacological drug development are also welcome.
With an immunoscience focus on drug development, immunotherapy and toxicology, the journal will cover areas such as infection, allergy, inflammation, tumor immunology, degenerative disorders, immunodeficiencies, neurology, atherosclerosis and more.
Immunopharmacology and Immunotoxicology will accept original manuscripts, brief communications, commentaries, mini-reviews, reviews, clinical trials and clinical cases, on the condition that the results reported are based on original, clinical, or basic research that has not been published elsewhere in any journal in any language (except in abstract form relating to paper communicated to scientific meetings and symposiums).